EASO Frameworkโ forโ Obesity Treatment Reveals โExtensive Industry Ties Among Authors
New guidelines for the pharmacological treatment of obesity andโข its complications, released โby the โฃEuropean Association for the โฃStudy of Obesity (EASO), haveโข surfaced with disclosures revealing significant financial โconnections between several authors and pharmaceutical companies developing and marketing โobesity drugs. The disclosures, detailed โin the published article, highlight potential conflictsโ of interestโฃ that warrant scrutiny asโฃ healthcare professionals consider implementing the EASO’s recommendations.
Several authors โฃreport receivingโ honoraria, consulting fees, research grants, and speaker feesโฃ from major pharmaceutical companies including Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi, and others. B.M. has receivedโข speaker and/or advisory fees from Novo Nordisk, Eli-Lilly, Astra โขZeneca, Janssen, Pfizer, MSDโ and a research grant from Novo Nordisk; andโค is a shareholder of reset health. A.C. discloses speaking fees from multiple companies, research grants from Eli Lilly and NovoNordisk, and membership on a Boehringer Ingelheim data monitoring commitee. J.L.B. received a consultingโ fee from Novo Nordiskโ A/S, paid to her institution.L.B. reports honoraria from a โฃbroad range of companies including Regeneron โคand Rhythm Pharmaceuticals. D.D. received speaker and advisoryโฃ board fees, as well as research grants,โ from several keyโค players in the obesity treatment market.G.F. received honoraria from Eli Lilly, Novo Nordisk, โฃRegeneron and Astra โฃZeneca, and was a member of theโ OPEN Spain โคInitiative. Matteo Monami receivedโ speaking fees and research โคgrants fromโฃ numerous companies, including Bristol Myers Squibb and Novartis.P.S.โ receivedโ honoraria and consulting fees โfrom Boehringer Ingelheim, โChiesi, Novo Nordisk, Eli Lilly, โฃPfizer, andโ Roche. B.M.-T. received grants fromโ the โEASO Newโ Clinical Investigator Award 2024 and the EFSD Rising โฃStar 2024, both supported by the Novo Nordisk Foundation.โ V.Y. engaged โin advisory boards and lectures with novo โNordisk, Eliโข Lilly,โ Rhythmโข and Regeneron.
Notably, G.G.and E.W. declared no conflicts of interest.
The EASO frameworkโ aims to provideโฃ a extensive approach to obesity โmanagement, encompassing lifestyle interventions and pharmacological options. The disclosures raiseโ questions about the potential influence of industry โfunding on the progress andโข presentation of these guidelines, โprompting calls for transparency and independent evaluation of โtreatment recommendations.